Repligen Corp.

-3.02 (-1.10%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)14.89B
Current PE148.99
Forward PE 97.77
2yr Forward PE 88.5
See more stats
Estimates Current Quarter
Revenue$163.97 Million
Adjusted EPS$0.64
See more estimates
10-Day MA$270.41
50-Day MA$281.23
200-Day MA$224.08
See more pivots

Repligen Corp. Stock, NASDAQ:RGEN

41 Seyon Street, Building 1, Waltham, Massachusetts 02453
United States of America
Phone: +1.781.250.0111
Number of Employees: 1128


Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.